Literature DB >> 16232216

Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy.

M Montes1, N Rufer, V Appay, S Reynard, M J Pittet, D E Speiser, P Guillaume, J-C Cerottini, P Romero, S Leyvraz.   

Abstract

Increasing evidence suggests that adoptive transfer of antigen-specific CD8(+) T cells could represent an effective strategy in the fight against chronic viral infections and malignancies such as melanoma. None the less, a major limitation in the implementation of such therapy resides in the difficulties associated with achieving rapid and efficient expansion of functional T cells in culture necessary to obtain the large numbers required for intravenous infusion. Recently, the critical role of the cytokines interleukin (IL)-2, IL-7 and IL-15 in driving T cell proliferation has been emphasized, thus suggesting their use in the optimization of expansion protocols. We have used major histocompatibility complex (MHC) class I/peptide multimers to monitor the expansion of antigen-specific CD8 T lymphocytes from whole blood, exploring the effect of antigenic peptide dose, IL-2, IL-7 and IL-15 concentrations on the magnitude and functional characteristics of the antigen-specific CD8(+) T cells generated. We show here that significant expansions of antigen-specific T cells, up to 50% of the CD8(+) T cell population, can be obtained after a single round of antigen/cytokine (IL-2 or IL-15) stimulation, and that these cells display good cytolytic and interferon (IFN)-gamma secretion capabilities. Our results provide an important basis for the rapid in vitro expansion of autologous T cells from the circulating lymphocyte pool using a simple procedure, which is necessary for the development of adoptive transfer therapies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16232216      PMCID: PMC1809512          DOI: 10.1111/j.1365-2249.2005.02914.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  48 in total

1.  IL-15 promotes the survival of naive and memory phenotype CD8+ T cells.

Authors:  Marion Berard; Katja Brandt; Silvia Bulfone-Paus; David F Tough
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

2.  Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines.

Authors:  Jens Geginat; Antonio Lanzavecchia; Federica Sallusto
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

3.  Homeostasis of naive and memory CD4+ T cells: IL-2 and IL-7 differentially regulate the balance between proliferation and Fas-mediated apoptosis.

Authors:  Sara Jaleco; Louise Swainson; Valérie Dardalhon; Maryam Burjanadze; Sandrina Kinet; Naomi Taylor
Journal:  J Immunol       Date:  2003-07-01       Impact factor: 5.422

4.  Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA.

Authors:  Danielle Liénard; Donata Rimoldi; Marie Marchand; Pierre-Yves Dietrich; Nicolas van Baren; Christine Geldhof; Pascal Batard; Philippe Guillaume; Maha Ayyoub; Mikaël J Pittet; Alfred Zippelius; Katharina Fleischhauer; Ferdy Lejeune; Jean-Charles Cerottini; Pedro Romero; Daniel E Speiser
Journal:  Cancer Immun       Date:  2004-05-19

5.  Culturing of HIV-1-specific cytotoxic T lymphocytes with interleukin-7 and interleukin-15.

Authors:  Rachel Lubong; Hwee L Ng; Christel H Uittenbogaart; Otto O Yang
Journal:  Virology       Date:  2004-08-01       Impact factor: 3.616

6.  IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.

Authors:  Christopher A Klebanoff; Steven E Finkelstein; Deborah R Surman; Michael K Lichtman; Luca Gattinoni; Marc R Theoret; Navrose Grewal; Paul J Spiess; Paul A Antony; Douglas C Palmer; Yutaka Tagaya; Steven A Rosenberg; Thomas A Waldmann; Nicholas P Restifo
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-04       Impact factor: 11.205

7.  Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells.

Authors:  Petra Hoffmann; Ruediger Eder; Leoni A Kunz-Schughart; Reinhard Andreesen; Matthias Edinger
Journal:  Blood       Date:  2004-04-15       Impact factor: 22.113

Review 8.  Adoptive-cell-transfer therapy for the treatment of patients with cancer.

Authors:  Mark E Dudley; Steven A Rosenberg
Journal:  Nat Rev Cancer       Date:  2003-09       Impact factor: 60.716

9.  IL-15 induces antigen-independent expansion and differentiation of human naive CD8+ T cells in vitro.

Authors:  Nuno L Alves; Berend Hooibrink; Fernando A Arosa; René A W van Lier
Journal:  Blood       Date:  2003-06-12       Impact factor: 22.113

10.  Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

Authors:  Willem W Overwijk; Marc R Theoret; Steven E Finkelstein; Deborah R Surman; Laurina A de Jong; Florry A Vyth-Dreese; Trees A Dellemijn; Paul A Antony; Paul J Spiess; Douglas C Palmer; David M Heimann; Christopher A Klebanoff; Zhiya Yu; Leroy N Hwang; Lionel Feigenbaum; Ada M Kruisbeek; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2003-08-18       Impact factor: 14.307

View more
  14 in total

1.  Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy.

Authors:  Matthias Wölfl; Katharina Merker; Henner Morbach; Stefaan W Van Gool; Matthias Eyrich; Philip D Greenberg; Paul G Schlegel
Journal:  Cancer Immunol Immunother       Date:  2010-10-24       Impact factor: 6.968

2.  Adoptive T Regulatory Cell Therapy for Tolerance Induction.

Authors:  Cecilia Cabello-Kindelan; Shane Mackey; Allison L Bayer
Journal:  Curr Transplant Rep       Date:  2015-06-01

3.  Fumarates target the metabolic-epigenetic interplay of brain-homing T cells in multiple sclerosis.

Authors:  Achilles Ntranos; Vasilis Ntranos; Valentina Bonnefil; Jia Liu; Seunghee Kim-Schulze; Ye He; Yunjiao Zhu; Rachel Brandstadter; Corey T Watson; Andrew J Sharp; Ilana Katz Sand; Patrizia Casaccia
Journal:  Brain       Date:  2019-03-01       Impact factor: 13.501

4.  Public and private human T-cell clones respond differentially to HCMV antigen when boosted by CD3 copotentiation.

Authors:  Laura R E Becher; Wendy K Nevala; Shari Lee Sutor; Megan Abergel; Michele M Hoffmann; Christopher A Parks; Larry R Pease; Adam G Schrum; Svetomir N Markovic; Diana Gil
Journal:  Blood Adv       Date:  2020-11-10

5.  Stimulation by means of dendritic cells followed by Epstein-Barr virus-transformed B cells as antigen-presenting cells is more efficient than dendritic cells alone in inducing Aspergillus f16-specific cytotoxic T cell responses.

Authors:  F Zhu; G Ramadan; B Davies; D A Margolis; C A Keever-Taylor
Journal:  Clin Exp Immunol       Date:  2007-11-14       Impact factor: 4.330

6.  Rapid identification of MHC class I-restricted antigens relevant to autoimmune diabetes using retrogenic T cells.

Authors:  Rodolfo José Chaparro; Amanda R Burton; David V Serreze; Dario A A Vignali; Teresa P DiLorenzo
Journal:  J Immunol Methods       Date:  2008-04-08       Impact factor: 2.303

7.  KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity.

Authors:  Mojca Skoberne; Alice Yewdall; Keith S Bahjat; Emmanuelle Godefroy; Peter Lauer; Edward Lemmens; Weiqun Liu; Will Luckett; Meredith Leong; Thomas W Dubensky; Dirk G Brockstedt; Nina Bhardwaj
Journal:  J Clin Invest       Date:  2008-11-06       Impact factor: 14.808

8.  Senescent Cells with Augmented Cytokine Production for Microvascular Bioengineering and Tissue Repairs.

Authors:  Yang Xiao; Chang Liu; Zhuo Chen; Michael R Blatchley; Dongjoo Kim; Jing Zhou; Ming Xu; Sharon Gerecht; Rong Fan
Journal:  Adv Biosyst       Date:  2019-05-27

Review 9.  Genetically modified T cells in cancer therapy: opportunities and challenges.

Authors:  Michaela Sharpe; Natalie Mount
Journal:  Dis Model Mech       Date:  2015-04-01       Impact factor: 5.758

10.  Expanded Human Blood-Derived γδT Cells Display Potent Antigen-Presentation Functions.

Authors:  Mohd Wajid A Khan; Stuart M Curbishley; Hung-Chang Chen; Andrew D Thomas; Hanspeter Pircher; Domenico Mavilio; Neil M Steven; Matthias Eberl; Bernhard Moser
Journal:  Front Immunol       Date:  2014-07-23       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.